Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000011.xml
Dtsch Med Wochenschr 2008; 133(39): 1958-1962
DOI: 10.1055/s-0028-1085603
DOI: 10.1055/s-0028-1085603
Arzneimittel & Pharmakotherapie | Review article
Neurologie
© Georg Thieme Verlag KG Stuttgart · New York
Olanzapin
OlanzapineFurther Information
Publication History
eingereicht: 1.2.2008
akzeptiert: 14.5.2008
Publication Date:
16 September 2008 (online)

Einleitung
Olanzapin (Zyprexa®) ist ein zur chemischen Klasse der Thienobenzodiazepin-Derivate gehörender Serotonin-Dopamin-Rezeptorantagonist. Es wurde 1996 in der EU nach Clozapin und Risperidon als drittes atypisches Neuroleptikum zur Behandlung schizophrener Störungen eingeführt. Es ist mit Clozapin, dem Prototyp dieser Arzneimittelgruppe, chemisch eng verwandt.
Literatur
- 1 Agelink M W, Majewski T, Wurthmann C. et al . Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine. J Clin Psychopharmacol. 2001; 21 8-13
- 2 Allison D B, Mentore J L, Heo M. et al . Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999; 156 1686-96
- 3 Arzneimittelkommission der deutschen Ärzteschaft . Blutbildveränderungen unter dem neueren atypischen Neuroleptikum Olanzapin. Dtsch Aerztbl. 2001; 3 130
- 4 Arznei-Telegramm. 2000 31: 31-2
- 5 Arznei-Telegramm. 2004 35: 2-4
- 6 Arznei-Telegramm. 2005 36: 51-2
- 7 Beasley Jr C M, Sanger T, Satterlee W. et al . Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl). 1996; 124 159-67
- 8 Berk M, Ichim L, Brook S. Olanzapine compared to lithium in mania: a double-blind randomized controlled trial. Int Clin Psychopharmacol. 1999; 14 339-43
- 9 Bryden K E, Kopala L C. Body mass index increase of 58 % associated with olanzapine. Am J Psychiatry. 1999; 156 1835-6
- 10 Callaghan J T, Bergstrom R F, Ptak L R. et al . Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999; 37 177-93
- 11 Consensus development conference on antipsychotic and obesity and diabetes. Diabetes Care. 2004; 27 596-601
- 12 Fachinformation. Zyprexa, Olanzapin. Stand 2006
- 13 Henderson D C, Cagliero E, Copeland P M. et al . Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry. 2005; 62 19-28
- 14 Jayaram M B, Hosalli P, Stroup S. Risperidone versus olanzapine for schizophrenia. Cochrane Database Syst Rev 2006 CD005237
- 15 Kinon B J, Lieberman J A. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology (Berl). 1996; 124 2-34
- 16 Lieberman J A, Stroup T S, McEvoy J P. et al . Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353 1209-23
- 17 Lindenmayer J P, Khan A, Iskander A. et al . A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. J Clin Psychiatry. 2007; 68 368-79
- 18 Rabinowitz J, Lichtenberg P, Kaplan Z. et al . Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am J Psychiatry. 2001; 158 266-9
- 19 Sacchetti E, Valsecchi P, Parrinello G. A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial. Schizophr Res. 2008; 98 55-65
- 20 Schwabe U PD. Arzneiverordnungs-Report 2006. Heidelberg; Springer-Verlag 2007
- 21 Stroup T S, McEvoy J P, Swartz M S. et al . The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull. 2003; 29 15-31
- 22 Tandon R. Safety and tolerability: how do newer generation „atypical” antipsychotics compare?. Psychiatr Q. 2002; 73 297-311
- 23 Tohen M, Greil W, Calabrese J R. et al . Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry. 2005; 162 1281-90
- 24 Tohen M, Sanger T M, McElroy S L. et al . Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry. 1999; 156 702-9
- 25 Tollefson G D, Beasley Jr C M, Tamura R N. et al . Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry. 1997; 154 1248-54
- 26 Tran P V, Dellva M A, Tollefson G D. et al . Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. Br J Psychiatry. 1998; 172 499-505
- 27 Tran P V, Hamilton S H, Kuntz A J. et al . Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol. 1997; 17 407-18
Katrin Wittköpper
Institut für Experimentelle und Klinische
Pharmakologie und Toxikologie, Universitätsklinikum
Hamburg-Eppendorf, Hamburg
Martinistraße 52
20246 Hamburg
Phone: 040 42803/2180
Fax: 040 42803/4876